Luca Fischer

5PUBLICATIONS
18CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Liquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Apr 27, 2024
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.

Luca Fischer, Linmiao Jiang, Jan Dürig

|Aug 08, 2023
The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysis.

Luca Fischer, Linmiao Jiang, Joerg Thomas Bittenbring

|Jun 10, 2023
Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimus.

Marie Moosburner, Lamija Alibegovic, Korbinian Hasselmann

|Apr 16, 2023
Follicular lymphoma: an update on biology and optimal therapy.

Luca Fischer, Martin Dreyling

|Aug 16, 2022
Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma.

Gilles Salles, Stephen J Schuster, Martin Dreyling

Pageof 1

Frequent Collaborators

1 joint publications

Gilles Salles

1 joint publications

Stephen J Schuster

1 joint publications

Martin Dreyling

1 joint publications

Piers E M Patten